Medipharm Labs Corp T.LABS

Shareholder value

[NoRiskNoReward]

Management needs to start thinking outside the box to bring existing shareholders more value. Doing a M&A at current share price would be a slap in the face. If management is so confident on being cash flow positive in the next 2 quarters and pending news with a pharma partner. I'd rather see them do a 10-1 reverse split, followed by a share buyback with the money from Tilray settlement. We could potentially be at at the same outstanding shares prior to the Vivo acquisition. I think that would be the best 1-2 punch we need to wake up this stock.

[subaru1i]

FDA or ANVISA approval will do that and MUCH more for the stock price.  A reverse split does nothing except increase volatility at the new price point with less shares circulating.  Share buyback would send the loudest signal to shake things up.   We need to see the name of their "traditional global pharmaceutical partner"....with the right name, that would shake

[Solid1]

Japan clears the way for cannabinoid-containing medicines! BIG! Japan has draconian penalties against cannabis, but when even a country like this recognizes the benefits of cannabinoid therapies, we're in for a big surprise 

[Marv1010]

You think doing a 10:1 RS isn't a slap in the face of current shareholders?  haha. I agree that at this point M&A isn't the right look but neither is doing a RS when it would punish long term shareholders.  I agree that a buyback would make lots of sense at this level but really, if mgmt are confident in the pharma angle, we could see billion dollar market caps in a blink

[NoRiskNoReward]

If Medipharm Labs put a $8 million wall at $.65 it will help de risk the reverse split. Any positive new will be reflected on the upside.  the problem we have is there is not that many new investors wanting to invest. Our stock has no pulse, it's been dead for 2 years. When the nr dropped about us collecting roughly 30% of our market cap from Tilray our stock did absolutely nothing

[Marv1010]

The stock has no pulse because the cannabis hype train has left the station and this business (like most normal ones) is being judged on what have you done for me lately. LABS was never a stock that benefited from any of the hype appreciation when hype in cannabis was a thing, now that it's not, nothing will move the SP appreciably except for the pharma unicorn.  We'll get a bump

[checkup]

At one point (in the beginning) LABS stood out from the crowd because of its strategic managing of its business.  I don't think a reverse split would do any good.  10 to 1 would leave 39 million shares outstanding and a share price of .60 cents. A buyout is probably the best we'll get. It is being affected by tax loss selling too.  The business segment would benefit from

[subaru1i]

500e6 shares is about the bottom limit of float for some institutionals before even thinking of taking a respectable position in a stock, especially pension funds that are managed by the likes of CIBC Mellon and this is normal as an approach to risk management.    The entire cannabis segment, recreational or pharmaceuticals has been burned to the ground by hype, speculation and dreams

[okgonow]

RS = kiss of death and a kick to the groin for us shareholders  if you want to create value for existing shareholders and reduce float the sharebuyback is the ONLY and best solution. show the rest of the market the company believes in itself to buy up all and any shares under lets say $.010 on an ongoing basis. put a floor under the SP that cant be breeched and watch the shorters get whats

[NoRiskNoReward]

Just a little fyi, kiss of death occurs when a company is forced to do a RS to stay on the exchange, followed by them diluting to fill the piggy bank up again.  A voluntary RS, followed by a share buyback is not the same outcome. 

[subaru1i]

CEO is showing a vote of confidence, holding onto his awarded shares, now over 3% ownership of the company  BUT a buyback of shares at these depressed prices would send an even stronger message to all shareholders that this company is serverely undervalued.   For example, a small buyback of $6 million out of their cash pile would reduce the float by 75 million shares AT pps of $.08.